Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH
* Boehringer Ingelheim commences Phase II program of investigational drug candidate BI 1467335 acquired from Pharmaxis with a 12 week Phase IIa proof of clinical principle study in non-alcoholic steatohepatitis (NASH) * New study underscores Boehringer Ingelheim's aspiration to deliver more ...
2017-08-25 08:39
3564
Boehringer Ingelheim Acquires Pharmaxis' Phase 1 Anti-inflammatory Drug Candidate
FRENCHS FOREST, Australia and INGELHEIM, Germany, May 18, 2015 /PRNewswire/ -- * Boehringer Ingelheim exercises option and acquires global ownership of Pharmaxis' investigational anti-inflammatory drug candidate PXS4728A, including associated intellectual property rights. * PXS4728A is a hig...
2015-05-18 11:19
2372
